Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 19.01.2026 7 Ann Surg Oncol 6 BMC Cancer 1 BMJ 1 Br J Cancer 1 Breast Cancer (Dove Med Press) 6 Breast Cancer Res 2 Breast Cancer Res Treat 2 Breast J 1 Cancer Res 1 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 1 Eur J Surg Oncol 1 Histopathology 3 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 2 J Natl Cancer Inst 1 J Surg Oncol 1 NPJ Breast Cancer 1 Oncol Rep 3 PLoS One 1 Radiol Imaging Cancer 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. ABDULLA HA, McGarry J, Kaczorowska R, Grealish A, et al
   Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.
   Ann Surg Oncol. 2026 Jan 16. doi: 10.1245/s10434-025-19070.
   PubMed         Abstract available
   
   
2. HOLMES DR, Manoian S, Rahman RL, Ward RC, et al
   Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial.
   Ann Surg Oncol. 2026 Jan 15. doi: 10.1245/s10434-025-18991.
   PubMed         Abstract available
   
   
3. DOUGLAS SR, Thomas SM, Chiba A, Botty van den Bruele A, et al
   ASO Author Reflections: Moving Toward Evidence-Based Guidelines for Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.
   Ann Surg Oncol. 2026 Jan 14. doi: 10.1245/s10434-025-18331.
   PubMed        
   
   
4. CHEN C, Ru L
   Prognostic Associations Between Adjuvant Chemotherapy and Survival in T1b-T2N0M0 Medullary Breast Cancer: A Population-Based Study of 2343 Patients.
   Ann Surg Oncol. 2026 Jan 14. doi: 10.1245/s10434-025-19054.
   PubMed         Abstract available
   
   
5. DZUBNAR JM, Habel LA, Jiang SF, Karlea A, et al
   Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.
   Ann Surg Oncol. 2026 Jan 13. doi: 10.1245/s10434-025-19053.
   PubMed         Abstract available
   
   
6. ROSS VMS, Addie M, Pickard MR, Josey V, et al
   ASO Visual Abstract: Axillary Management in Patients with Breast Cancer with Positive Lymph Nodes Following Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2026 Jan 12. doi: 10.1245/s10434-025-19036.
   PubMed        
   
   
7. GNANGNON FHR, Parente A, Allayambaye TE, Sacca HR, et al
   Epidemiology and Clinical Features of Breast Cancer in Cotonou (2014-2019): Insights from a Population-Based Registry Study.
   Ann Surg Oncol. 2026 Jan 11. doi: 10.1245/s10434-025-18976.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. CHEKHUN V, Lukianova Y, Mushii O, Zadvornyi T, et al
   Breast cancer microenvironment composition associated with high PD-L1 expression.
   BMC Cancer. 2026 Jan 14. doi: 10.1186/s12885-026-15542.
   PubMed         Abstract available
   
   
9. ELALFY E, Gaber NE, Helmy MH, Kamel MA, et al
   Scrutinizing the potential role of non-coding RNAs as biomarkers in Egyptian females with early and metastatic breast cancer.
   BMC Cancer. 2026 Jan 14. doi: 10.1186/s12885-025-15483.
   PubMed        
   
   
10. ZHANG C, Li S, Ren J, Wen X, et al
    Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15561.
    PubMed        
    
    
11. PETER M, Swaminathan N, Govindharaj P
    Development of culture specific quality of life tool for breast cancer survivors of Indian population.
    BMC Cancer. 2026 Jan 10. doi: 10.1186/s12885-026-15563.
    PubMed         Abstract available
    
    
12. SHI QF, Hu PF, Liu YH
    Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15545.
    PubMed         Abstract available
    
    
13. CHOUDHARY A, Poojary SS, Jain P, Chaturvedi H, et al
    Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-025-15499.
    PubMed         Abstract available
    
    

    
    BMJ

14. 
    Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
    BMJ. 2026;392:s43.
    PubMed        
    
    

    
    Br J Cancer

15. PRAUD D, Amadou A, Mercoeur B, Duboeuf M, et al
    Long-term atmospheric exposure to particulate matter and breast cancer risk: findings from a nested case-control study in France.
    Br J Cancer. 2026 Jan 13. doi: 10.1038/s41416-025-03311.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

16. LIANG J, Tang M, Wang L
    The Novel ROCK Inhibitor Fasudil Derivative Fasudil-D-6h Prevents Tumour Progression by Regulating the Adherens Junction Signalling Pathway in Triple-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:1-13.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

17. TIKUM AF, Fon DA, Njotu FN, Henning N, et al
    [(225)Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.
    Breast Cancer Res. 2026 Jan 16. doi: 10.1186/s13058-026-02220.
    PubMed         Abstract available
    
    
18. TROISI R, Falk RT, Surcel HM, Kauppila S, et al
    Estrogen metabolism pathways in pregnancy and subsequent breast cancer risk: a prospective follow-up study.
    Breast Cancer Res. 2026 Jan 16. doi: 10.1186/s13058-025-02204.
    PubMed         Abstract available
    
    
19. YAN Y, Narayan A, Mazinani M, Saeki H, et al
    CRYbetaB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer.
    Breast Cancer Res. 2026 Jan 14. doi: 10.1186/s13058-025-02188.
    PubMed        
    
    
20. RONY R, Deng S, Yang S, Doig K, et al
    Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases.
    Breast Cancer Res. 2026;28:5.
    PubMed         Abstract available
    
    
21. MOSQUIM JUNIOR S, Zamore M, Vallon-Christersson J, Ryden L, et al
    Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread.
    Breast Cancer Res. 2026;28:12.
    PubMed         Abstract available
    
    
22. PANTALEO J, Sjolund J, Bolivar P, Bocci M, et al
    Spatial and temporal dynamics of cancer-associated fibroblast niches in breast cancer.
    Breast Cancer Res. 2026 Jan 11. doi: 10.1186/s13058-025-02183.
    PubMed        
    
    

    
    Breast Cancer Res Treat

23. LEITZELAR BN, Willis AR, Price SN, Tooze JA, et al
    Updated systematic review and meta-analysis: taking the next step in physical activity behavioral interventions for post-treatment breast cancer survivors.
    Breast Cancer Res Treat. 2026;215:56.
    PubMed         Abstract available
    
    
24. BLUM M, Koch SM, Mousavi M, Vorburger D, et al
    Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis.
    Breast Cancer Res Treat. 2026;215:57.
    PubMed         Abstract available
    
    

    
    Breast J

25. SCHEMMEL N, Lauberger J, Luhnen J, Steckelberg A, et al
    Information Needs and Preferences of Men With Breast Cancer: A Qualitative Analysis of Internet Forum Posts.
    Breast J. 2026;2026:8821629.
    PubMed         Abstract available
    
    
26. SILAFU B, Huang J, Aizezi X
    Expression Characteristics of PAX7 and Its Prognostic Correlation in Breast Cancer.
    Breast J. 2026;2026:3060151.
    PubMed         Abstract available
    
    

    
    Cancer Res

27. JIANG HL, Sun HF, Gao SP, Li LD, et al
    Retraction: SSBP1 Suppresses TGFbeta-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling.
    Cancer Res. 2026;86:557.
    PubMed        
    
    

    
    Clin Breast Cancer

28. SHEN A, Yang Y, Zhang L, Lukkahatai N, et al
    When Obesity Meets Lymphedema: Interaction Effects on Lymphatic Pain Among Chinese Breast Cancer Survivors.
    Clin Breast Cancer. 2025;26:36-44.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

29. HACHEY J, Viray TD, Carrasco SE, Carter LM, et al
    Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast Cancer.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-3354.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

30. VALDERRAMA NF, Morel LO, Mweze DT, Derangere V, et al
    Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2026;234:116222.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

31. LOI F, Rassy E, Grinda T, Puchar A, et al
    Targeted axillary dissection in breast cancer: current evidence and ongoing trials.
    Eur J Surg Oncol. 2025;52:111377.
    PubMed         Abstract available
    
    

    
    Histopathology

32. LLEWELLYN A, Brown A, Morel J, Naidoo K, et al
    To VAE or not to VAE: outcomes of radial scars/complex sclerosing lesions and papillary lesions without atypia in the King's College Hospital breast service (2017-2023).
    Histopathology. 2026;88:583-590.
    PubMed         Abstract available
    
    

    
    Int J Cancer

33. WANG P, O'Connell K, Bhimani J, Blinder V, et al
    Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings.
    Int J Cancer. 2026;158:1481-1488.
    PubMed         Abstract available
    
    
34. LIN X, Chen Z, Lin J, Huang C, et al
    (99m)Tc-HP-Ark2 SPECT/CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition.
    Int J Cancer. 2026;158:1726-1739.
    PubMed         Abstract available
    
    
35. HURSON AN, Butler EN, Hamilton AM, Shah KK, et al
    Etiology of gene expression-based subtypes of breast cancer in the Ghana Breast Health Study.
    Int J Cancer. 2026 Jan 16. doi: 10.1002/ijc.70332.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

36. BYUN DJ, Liu EK, Maisonet O, Xiao J, et al
    Curietherapy User eXperience pilot study (CurieUx): a feasibility study of a novel augmented reality educational tool during radiation oncology consultation for patients with breast cancer.
    Int J Radiat Oncol Biol Phys. 2026 Jan 13:S0360-3016(26)00015.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

37. VALENZA C, Zheng Y, Milano M, Trapani D, et al
    Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
    J Clin Oncol. 2026 Jan 15:JCO2501660. doi: 10.1200/JCO-25-01660.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

38. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    PubMed         Abstract available
    
    
39. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

40. NGUYEN AT, Duckworth ED, Li RA, Galiano RD, et al
    Disparities in Breast Cancer Screening, Diagnosis, and Outcomes Among Vietnamese American Women: A Systematic Review.
    J Surg Oncol. 2026 Jan 14. doi: 10.1002/jso.70164.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

41. LAM C, Lanchoney O, Maddipatla V, Markosyan N, et al
    Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer.
    NPJ Breast Cancer. 2026 Jan 13. doi: 10.1038/s41523-025-00889.
    PubMed         Abstract available
    
    

    
    Oncol Rep

42. ALVARES-VILELA MM, Schlemmer F, Ferrari SSAR, Xavier ME, et al
    Role of tumor?infiltrating lymphocytes and miR?155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review).
    Oncol Rep. 2026;55:42.
    PubMed         Abstract available
    
    

    
    PLoS One

43. 
    Retraction: Phospho-Aspirin-2 (MDC-22) Inhibits Estrogen Receptor Positive Breast Cancer Growth Both In Vitro and In Vivo by a Redox-Dependent Effect.
    PLoS One. 2026;21:e0341199.
    PubMed        
    
    
44. LIU C, Ren Y, Luo X, Zhou P, et al
    Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV.
    PLoS One. 2026;21:e0338127.
    PubMed         Abstract available
    
    
45. YU H, Zhao J, Wu D, Yuan H, et al
    Exosome encapsulated albumin nanoparticles target delivery of DBET6 as a treatment for triple-negative breast cancer.
    PLoS One. 2026;21:e0335890.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

46. ZHANG J
    From Voxel-wise Fitting to Generative Translation: A Path for Quantitative DCE MRI Analysis in Breast Cancer.
    Radiol Imaging Cancer. 2026;8:e250669.
    PubMed        
    
    

    
    Radiology

47. MAHMOUD MA, Chen J, Edmonds CE, Fayanju OM, et al
    Black-White Racial Differences in Background Parenchymal Enhancement at Breast MRI.
    Radiology. 2026;318:e251041.
    PubMed         Abstract available
    
    
48. CHANG JM, Leung JWT, Heacock L, Lee SH, et al
    Breast US: State of the Art.
    Radiology. 2026;318:e233101.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.